MANIFESTATIONS OF TUMORASSOCIATED ANEMIA IN MICE WITH LEWIS LUNG CARCINOMA AT THE BACKGROUND OF USE OF CANCER VACCINES
Keywords:
paraneoplastic syndrome, tumorassociated anemia, Lewis lung carcinoma LLC/R9, cancer vaccine, effectiveness, anticancer resistance.Abstract
Summary. The study of the mechanisms of paraneoplastic syndrome (PNS) formation and the search for
the ways of its correction remains actual. Aim: to study
possible correction of some PNS manifestations caused
by the development of high angiogenic Lewis lung carcinoma using cancer vaccines (CaV) on the basis of high
angiogenic (LLC/R9) or low angiogenic (LLC) strains
of Lewis lung carcinoma, and also to assess antitumor and immunologic effects of CaV. Object and methods: the study was performed on male С57Bl/6 mice
with transplanted LLC/R9. CaV was prepared from
LLC cells (CaV-LLC) or LLC/R9 cells (CaV-LLC/
R9); 70 kD protein-containing metabolite of B. subtilis B-7025 was used as an adjuvant. Administration
of CaV (4 times, subcutaneously) has been started on
the 12th day of tumor growth. Standard parameters of
tumor growth were assessed; on the 33rd day the level
of lung metastasis was assessed, and immunologic examination of the animals was performed (weight and
cellular parameters of thymus and spleen, peripheral
blood indexes (using hematologic analyzer), cytotoxic
activity (CTA) of cellular and humoral elements of unspecific and specific antitumor immunity with the use
of МТТ test). Results: the use of both CaV increased
the survival of mice with LLC/R9: on the 30th day of
tumor growth in the groups of vaccinated animals this
index was equal to 100.0% versus 71.4% in the control group. Significant decrease of the quantity and
volume of metastases (by 1.7-fold and 1.8-fold, respectively, p < 0.05) was registered just in «CaV-LLC»
group. Both vaccines did not prevent the development
of tumor-associated anemia and splenomegaly. Administration of Cav-LLC resulted in the increase of CTA
of natural killer cells (p < 0.05 compared with intact
control); prevented negative influence of the tumor on
characteristics of thymus, specific CTA of splenocytes,
and CTA of macrophages in the presence of blood serum. Conclusions: the obtained results create a background for the development of the indications for CaV
usage with consideration of PNS manifestations.
References
Boyiadzis M, Lieberman FS, Geskin LJ, et al. Paraneoplastic
syndromes. In: Cancer: principles and practice of oncology. 8th ed.
VT DeVita, TS Lawrence, SA Rosenberg, editors. New York: Lippincott, Williams & Wilkins, 2008: 2343–62.
Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc 2010; 85 (9):
–54.
Bilynsky BT, Dzhus MB, Litvinyak RI. The conceptual and
clinical problems of paraneoplastic syndrome in oncology and internal medicine. Exp Oncol 2015; 37: 82–8.
Manger B, Schett G. Paraneoplastic syndromes in rheumatology. Nat Rev Rheumatol 2014; 10 (11): 662–70.
Hirokawa M. Paraneoplastic autoimmune disorders. Japan
J Cancer Chemother 2010; 37: 980–3.
Григорович НА, Кашкан ТМ, Дорофтиенко СФ. Частоты встречаемости симптомов и синдромов злокачественных
новообразований (материалы для разработки экспертных систем в онкологии). Мед Новости 2014; (1): 61–5.
Дворников АС. К вопросу о патогенезе паранеопластических процессов. Вестн новых мед технол 2011; XVIII (2):
–6.
Gandhi L, Johnson BE. Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Canc Netw 2006;
(6): 631–8.
Williamson BT, Foltz L, Leitch HA. Autoimmune syndromes
presenting as a paraneoplastic manifestation of myelodysplastic
syndromes: clinical features, course, treatment and outcome. Hematol Rep 2016; 8 (2): 6480.
Лаврова ВС, Чернова ЕН, Карпова ГВ и др. Дизрегуляторные процессы в системе крови при заболевании раком.
Бюлл Сиб Мед 2006; (2): 75–84.
Schwartz RN. Anemia in patients with cancer: incidence,
causes, impact, management, and use of treatment guidelines and
protocols. Am J Health Syst Pharm 2007; 64: S5–S13.
Debeljak N, Solár P, Sytkowski AJ. Erythropoietin and cancer: the unintended consequences of anemia correction. Front Immunol 2014; 5: Article 563: 1–14.
Piegari M, Ortiz S, Díaz Mdel P, et al. Characterization
of a murine lung adenocarcinoma (LAC1), a useful experimental model to study progression of lung cancer. J Exp Ther Oncol
; 9 (3): 231–9.
Пясковська ОМ, Соляник ГІ, Федорчук та ін. Спосіб
отримання модифікованого варіанта карциноми легень
Льюїса. Пат № 48525 Україна, МПК G 01 N 33/15. № u2009
; заявл 28.08.2009; опубл 25.03.2010, Бюл № 6.
Pyaskovskaya ON, Dasyukevich OI, Kolesnik DL, et al.
Changes in VEGF level and tumor growth characteristics during
Lewis lung carcinoma progression towards cis-DDP resistance.
Exp Oncol 2007; 29 (3): 197–202.
Fedorchuk OG, Pyaskovskaya OM, Skivka LM, et al. Paraneoplastic syndrome in mice bearing high-angiogenic variant of
Lewis lung carcinoma: Relations with tumor derived VEGF. Cytokine 2012; 57 (1): 81–8.
Пясковська ОМ, Горбик ГВ, Якшибаєва ЮР та ін.
Корекція пухлино-асоційованої анемії поліфенолами винограду. Фармакол лікарськ токсикол 2014: (1 (37)): 91–8.
Sarnatskaya VV, Nikolaev VG, Yushko LA, et al. Effect of
enterosorption on paraneoplastic symptom manifestation in mice
with highly angiogenic variant of Lewis lung carcinoma. Exp Oncol 2015; 37 (4): 255–61.
Potebnya GP, Voeykova IM, Lisovenko GS, et al.Antitumor
and antimetastatic activities of vaccine prepared from cisplatin-resistant Lewis lung carcinoma. Exp Oncol 2009; 31 (4): 226–30.
Кожем’якін ЮМ, Хромов ОС, Філоненко МА, Сайфетдінова ГА. Науково-практичні рекомендації з утримання лабораторних тварин та роботи з ними. К: Авіцена, 2002. 179 с.
Council Directive 2010/63/EU of 22 september 2010 on
the protection of animals used for scientific purposes. Official J
Eur Commun 2010; 276: 33–79.
Потебня ГП, Лісовенко ГС, Черемшенко НЛ, та ін.
Спосіб одержання протипухлинної аутовакцини Пат.
№57869 Україна. Заявл 15.06.2001; опубл 15.07.2003; Бюл №7.
Діденко ГВ. Розробка протипухлинних аутовакцин
на основі білоквмісних метаболітів B. subtilis B-7025 та їх
вплив на окремі реакції протипухлинного імунітету (експериментальні дослідження) [автореф дис… канд біол наук].
Київ: 2008. 19 с.
Балицкий КП, Шмалько ЮП. Стресс иметастазирование злокачественных опухолей. К.: Наукова думка, 1987. 244 с.
Клауса Дж. Лимфоциты. Методы. М: Мир, 1990. 395 с.
Mosmann T. Rapid colorimetric assay for cellular growth
and survival: Application to proliferation and cytotoxicity assays.
J Immunol Methods 1983; 65: 55–63.
Ковбасюк СА, Юдин ВМ, Кравченко СП. Иммуномодулирующее влияние циклофосфана при различных схемах
введения его мышам. Цитология 1985; (3): 316–21.
Сиденко АВ, Вишняков ВВ, Исаев СМ. Теория статистики. Учебник. М: МАКС-Пресс, 2011. 343 с.
Finn OJ. Cancer immunology. N Engl J Med 2008; 358
(25): 2704–15.
Киселева ЕП. Механизмы инволюции тимуса при опухолевом росте. Успехи совр биол 2004; 124 (6): 589–601.
Киселева ЕП, Крылов АВ, Старикова ЭА, Кузнецова СА.
Фактор роста сосудистого эндотелия и иммунная система.
Успехи совр биол 2009; 129 (4): 336–47.
